Roanoke Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Roanoke Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,000	Closed	-$58K	–	106
2022 Q4	$58K	Hold	10,000	–	–	0.03%	103
2022 Q3	$67K	Hold	10,000	–	–	0.03%	103
2022 Q2	$42K	Hold	10,000	–	–	0.02%	106
2022 Q1	$34K	Buy	+10,000	New	+$31.7K	0.01%	110

Roanoke Asset Management's CNCE Position: Q1 2023 in Review

Roanoke Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 10,000 shares — an estimated $58K sold.

Roanoke Asset Management first reported a position in CNCE in Q1 2022 and held it in 4 quarters. The position peaked at $67K in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

Roanoke Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Roanoke Asset Management sold 10,000 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $58K.
Roanoke Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2022 and held it in 4 quarters.
Roanoke Asset Management's Concert Pharmaceuticals, Inc. position peaked at $67K in Q3 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Roanoke Asset Management's 13F filing for Q1 2023, filed 2 May 2023.